The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme.
James J Vredenburgh
Consultant or Advisory Role - Merck/Schering-Plough; Roche/Genentech
Honoraria - Merck/Schering-Plough; Roche/Genentech
Annick Desjardins
Consultant or Advisory Role - Roche/Genentech
Katherine B. Peters
No relevant relationships to disclose
David A. Reardon
Consultant or Advisory Role - Merck/Schering-Plough; Roche/Genentech
Honoraria - Merck/Schering-Plough; Roche/Genentech
James Emmett Herndon
No relevant relationships to disclose
April D. Coan
No relevant relationships to disclose
John Kirkpatrick
No relevant relationships to disclose
Leighann Bailey
No relevant relationships to disclose
Stevie Threatt
No relevant relationships to disclose
John Howard Sampson
No relevant relationships to disclose
Allan H. Friedman
No relevant relationships to disclose
Henry S. Friedman
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech